navicon

X
Visioneering Inc.

About Us

Visioneering is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lens.

We believe that the NaturalVue MF contact lens is one of the most significant innovations in the optical design of Multifocal contact lenses in more than 20 years.

Compared to currently marketed Multifocal contact lenses, NaturalVue MF contact lenses offer substantial performance improvements and superior patient outcomes for patients with Presbyopia, a large and important patient population.

Furthermore, Visioneering is excited by the early levels of adoption of NaturalVue MF contact lenses by eye care practitioners treating children with Myopia, another large and important patient population.

Please take some time to learn more about the company behind Visioneering through the materials in this section of our website.

VTI and NaturalVue are committed to redefining vision for those aged seven to seventy

VTI and NaturalVue are committed to redefining vision for those aged seven to seventy

  • Annual Report

Subscribe
  • News and Updates

Conference Call Recording

Visioneering Technologies' Appendix 4C investor conference call recording

Visioneering Technologies – 11/4/2019

On 11 April, VTI released its Appendix 4C quarterly cash flow report, and hosted a conference call with investors to discuss the company's growth, global expansion and sales strategy. If you missed the call, you can listen here.

Listen Here

VTI News

New four-year NaturalVue data presented at GSLS consistently shows 90% decrease in myopic progression

Visioneering Technologies – 29/01/2019

At the Global Specialty Lens Symposium (GSLS) this month, VTI presented an update on clinical data of 11 children wearing the NaturalVue Multifocal for up to four years, demonstrating an approximate 90% decrease in myopic progression refractive error (RE).

Read More

VTI News

Stockhead: Visioneering triples annual revenue in 2018

Visioneering Technologies – 24/01/2019

Visioneering Technologies was recently featured in an article on small cap outlet Stockhead. The article says VTI tripled its revenue in calendar year 2018, compared to 2017. The company recently has seen strong growth in revenue and product shipments in the US, and launched the NaturalVue lens in Europe, Australia and New Zealand.

Read More

Conference Call Recording

Visioneering Technologies’ Appendix 4C investor conference call recording

Visioneering Technologies – 24/01/2019

On 24 January, VTI released its Appendix 4C quarterly cash flow report, and hosted a conference call with investors to discuss the company’s growth, global expansion and sales strategy. If you missed the call, you can listen here.

Listen Here

Conference Call Recording

Watch Sydney optometrist Jim Kokkinakis discuss the myopia and parenting on Nine’s TODAY Show

TODAY– 17/01/2019

Sydney optometrist Jim Kokkinakis recently appeared on Australian breakfast TV, discussing the myopia epidemic with Nine’s TODAY hosts. Kokkinakis gives parents advice on how they can protect their kids’ eyes, and the available treatment options, including VTI’s NaturalVue lens.

Watch Here

Conference Call Recording

Visioneering Technologies' Appendix 4C investor conference call recording

Visioneering Technologies – 15/10/2018

On Monday 15 October, Visioneering hosted an investor conference call following its Appendix 4C and cash flow report. If you missed this call, you can listen here.

Listen Here

VTI News

VTI appoints first Medilens Nordic AB as first European distributor

Biotech Dispatch – 9/10/2018

Visioneering recently announced that Medilens Nordic AB has been named an authorised distributor for the NaturalVue contact lens in the Nordic region, marking VTI’s first entry into Europe. Read about the news in Biotech Dispatch.

Read More

VTI News

VTI to attend leading myopia conference in Australia

Visioneering Technologies – 18/09/2018

Shortly after signing VTI's first international eye care practitioners in Australia, the Company is already reporting its first international revenue. As part of its continued expansion momentum, Visioneering will exhibit at the Orthoketarology Society of Oceania ("OSO") Congress 2018.

Read More

VTI News

Visioneering enters international market, signing agreement with Sydney optometrist Oliver Woo

Visioneering Technologies – 4/09/2018

Visioneering Technologies Inc has established its first account outside the US, signing Sydney optometrist Oliver Woo. Mr Woo is a leading specialist in the management of paediatric myopia.

Read More

Stephen Snowdy Video

Dr Stephen Snowdy speaks to Proactive Investors Australia about the NaturalVue lens, sales growth and global expansion

Proactive Investors Australia– 31/08/2018

Visioneering Technologies CEO Dr Stephen Snowdy recently spoke to Danielle Doporto, reporter at Proactive Investors Australia, about the revolutionary NaturalVue lens, growth of its US sales team, CE mark approval and plans for global expansion.

Watch Here

VTI News

Commercial expansion in sight: VTI featured in Dr Boreham’s Crucible

Stockhead – 29/08/2018

Each week, veteran small cap writer Tim Boreham provides analysis of ASX life science companies for his column, Dr Boreham’s Crucible. In this recent article, Tim provides a detailed analysis of Visioneering Technologies Inc.

Read More

Conference Call Recording

Visioneering Technologies Appendix 4C investor conference call recording

Visioneering Technologies – 27/07/2018

On Friday 27 July, Visioneering hosted an investor conference call following its Appendix 4C and cash flow report. If you missed this call, you can listen to the call here.

Listen Here

VTI News

Visioneering Technologies releases Appendix 4C Cash Flow Report for quarter ended 30 June

Visioneering Technologies – 27/07/2018

Today, Visioneering Technologies released its Appendix 4C Quarterly Cash Flow Report and investor update for the quarter ended 30 June. The report showed revenue growth of almost 10 percent to US$607k. Highlights include increased US sales momentum, progress toward international expansion and two product launches.

Read More

VTI News

Visioneering Technologies Unveils NaturalVue® Sphere with Comfort Enhancers

Visioneering Technologies – 22/06/2018

At the American Optometric Association (AOA) meeting held in Denver, CO today, Visioneering introduced its new enhanced NaturalVue® Sphere 1 Day Contact Lenses with CleanComfort® technology.

Read More

VTI News

Visioneering Technologies Launches NaturalVue Multifocal Contact Lenses in Plus Powers

Visioneering Technologies – 22/06/2018

Visioneering announced the availability of NaturalVue Multifocal® 1 Day Contact lenses in Plus Powers. This power expansion gives the NaturalVue Multifocal contact lens the most extensive power range in 0.25D steps of any daily disposable soft multifocal contact lens on the market.

Read More

Stephen Snowdy Video

Visioneering Technologies – an exciting first year as a listed company

Finance News Network – 11/05/2018

Stephen Snowdy met with Finance News Network's Jessica Amir earlier this month to discuss the company's highlights since listing, as well as the benefits of its contact lenses in treating paediatric myopia, presbyopia and astigmatism.

Watch Here

Stephen Snowdy Video

Visioneering CEO Dr Stephen Snowdy discusses how VTI’s NaturalVue MF technology is addressing the myopia epidemic

Visioneering Technologies – 30/04/2018

Did you know it is expected half the world will suffer from myopia by 2050? In this video, Dr Snowdy explains how Visioneering’s revolutionary 1-day contact lens NaturalVue MF has been shown to almost completely halt progression of myopia in children.

Watch Here

4C Investor Conference Call

Visioneering Technologies Appendix 4C investor conference call recording

Visioneering Technologies – 16/04/2018

On Monday 16 April, Visioneering hosted an investor conference call following its Appendix 4C and cash flow report. If you missed this call, you can listen to the recording here.

Listen Here

FY17 Results

VTI CEO Dr. Stephen Snowdy discusses the recent CE Mark achieved for NaturalVue

Mivision – 2/04/17

In this article, Visioneering Technologies CEO and Executive Director, Dr. Stephen Snowdy discusses the data presented at the Global Specialty Lens Symposium (GSLS) in Las Vegas, and the effect of its NaturalVue MF lenses on slowing the progression of myopia in children. Dr. Snowdy also discusses the recent CE Mark achieved in Europe.

Read More

FY17 Results

Visioneering Technologies 2017 Annual Report

Visioneering Technologies – 29/03/2018

Visioneering Technologies, Inc. (ASX:VTI) is pleased to present its Annual Report to Shareholders for 2017.

View the Report

Visioneering Technologies CEO Dr. Stephen Snowdy discusses the Company’s FY17 results

Visioneering Technologies CEO Dr. Stephen Snowdy discusses the Company’s FY17 results

Finance News Network – 14/03/17

Visioneering Technologies CEO and Executive Director, Dr. Stephen Snowdy, speaks with Jessica Amir of Finance News Network, discussing the Company’s FY17 results and forward plans.

Read More

TGA approval received for NaturalVue family of 1 day contact lenses

TGA approval received for NaturalVue family of 1 day contact lenses

Visioneering Technologies – 02/03/2018

Visioneering Technologies (ASX:VTI) announced it has received approval from the Australian Therapeutics Goods Administration (TGA) for its portfolio of proprietary NaturalVue® (etafilcon A) brand 1 day contact lenses.

Read More

CE Mark for NaturalVue

VTI achieves CE Mark for NaturalVue

Nine Finance – 01/02/2018

Visioneering Technologies, Inc. (ASX:VTI) has received European CE Mark for commercialisation of its portfolio of proprietary NaturalVue (etafilcon A) brand 1 day contact lenses. The CE Mark also allows VTI to prepare regulatory submissions to launch its products in additional countries.

Read More

CE Mark

Visioneering achieves CE Mark for NaturalVue family of 1 day contact lenses

Visioneering Technologies – 31/01/2018

Visioneering Technologies, Inc. (ASX:VTI) announced it has received European CE Mark for commercialisation in the EU of its portfolio of proprietary NaturalVue® (etafilcon A) brand daily contact lenses.

Read More

Update on NaturalVue and paediatric myopia

Update on NaturalVue and paediatric myopia

Visioneering Technologies – 28/01/2018

Visioneering Technologies, Inc. (ASX:VTI) recently announced data presented at the Global Specialty Lens Symposium (GSLS), highlighting the impact of NaturalVue Multifocal on paediatric myopia.

Read More

FY17 Results

Visioneering Technologies FY17 Results

Visioneering Technologies – 14/03/18

Visioneering Technologies Limited (ASX:VTI) CEO and Executive Director, Dr Stephen Snowdy, discusses the company's FY17 results.

Watch Here

Visioneering Technologies Receives TGA Approval

Visioneering Technologies Receives TGA Approval

Visioneering Technologies – 02/03/18

Visioneering Technologies, Inc. recently announced it has received approval from the Australian Therapeutic Goods Administration for its portfolio of proprietary NaturalVue brand 1 Day Contact Lenses, including Sphere, Toric, Multifocal and Multifocal Toric.

Read More

Visioneering Technologies Achieves CE Mark

Visioneering Technologies Achieves CE Mark

Visioneering Technologies – 31/01/18

Visioneering Technologies, Inc. recently announced it has received European CE Mark for commercialization in the European Union of its portfolio of proprietary NaturalVue brand 1 Day Contact Lenses, including Sphere, Toric, Multifocal and Multifocal Toric.

Read More

quarterly audio

Visioneering Technologies, Inc. Appendix 4C and Cash Flow Report

Visioneering Technologies – 21/01/18

On Tuesday 23 January, Visioneering hosted an investor conference call following its Appendix 4C and cash flow report. If you missed this call, please listen to the recording here.

Listen Here

quarterly audio

New Data Demonstrate VTI's Multifocal Contact Lenses Effective in Reducing Myopia Progression in Children by 96%

Visioneering Technologies – 21/10/17

Visioneering Technologies, Inc. announced the positive results of a new retrospective case series analysis on the impact of its NaturalVue Multifocal 1 Day Contact Lenses (NaturalVue MF) in children with myopia, or near-sightedness.

Read More

quarterly audio

Four emerging healthcare stories with near-term catalysts

Livewire – 08/01/18

In this piece, Morgan's Senior Analyst, Scott Power discusses Visioneering Technologies amongst other healthcare companies which project strong reporting results in January 2018.

Read More

quarterly audio

Visioneering wants to save Asia's youth from myopia epidemic

Stockhead – 12/12/17

Interview with Visioneering Technologies CEO Dr Stephen Snowdy, addressing the myopia epidemic in East Asian markets.

Read More

quarterly audio

Visioneering Technologies Inc (ASX:VTI) talks myopia data & sales

FNN – 13/12/17

Visioneering Technologies' CEO and Executive Director, Dr Stephen Snowdy, provides an update on the Company, its latest myopia data results and outlook for FY18.

Read More

quarterly audio

Visioneering Technologies, Inc. Appendix 4CX and Cash Flow investor conference call recording

Visioneering Technologies – 19/10/17

On Thursday 19 October, Visioneering hosted an investor conference call following its Appendix 4C and cash flow report. If you missed this call, please listen to the recording here.

Listen Here

Chinese patent

Visioneering Technologies wins Chinese patent for its myopia control lens

Proactive Investors Australia – 24/08/2017

Visioneering Technologies Inc. has received a patent allowance in China for the optical designs of its myopia progression control contact lenses. Additionally, Singapore recently allowed the company's patent that will broadly protect the use of its multi-focal designs in any vision care application, until the year 2036.

Read More

conference audio

Visioneering Technologies, Inc. Appendix 4C and Cash Flow investor conference call recording

Visioneering Technologies – 01/08/17

On Tuesday 1 August, Visioneering hosted an investor conference call following its Appendix 4C and cash flow report. If you missed this call, please listen to the recording here.

Listen Here

  • Investment Highlights

January 2019 Investor Presentation:
Net revenue tripled in 2018, growth and global expansion continues

Investor Presentation
Investment Highlights

  • Board & Leadership

  • In Sight

Case study: Brisbane optometrist Dr Kate Gifford’s insights on the myopia epidemic

Written by Dr Kate Gifford on 5/18/2018

Dr Kate Gifford (Johnson) is a practice owner of Gerry & Johnson Optometrists in Brisbane Australia. In this article, Kate shares her knowledge of myopia, its causes and treatment, and why we don’t talk about this global problem as much as we should.

Read More

Case study: how Visioneering is leading the charge against myopia progression

Written by Dr Thomas Aller on 5/18/2018

Dr Thomas A Aller is an internationally known US optometrist currently practicing in San Bruno, California. His optometry practice specialises in treating myopia or nearsightedness. In this piece, Dr Aller examines the myopia epidemic, current treatment, and the study he is currently undertaking with Visioneering’s NaturalVue Multifocal contact lens.

Read More

Introduction to myopia infographic: what is myopia and how is Visioneering Technologies addressing this disease?

Written by Stephen Snowdy, PhD on 5/8/2018

Myopia or near-sightedness is a growing global issue affecting an alarming number of children worldwide. A fast-growing problem, it is estimated that half the world will be nearsighted by year 2050. See the infographic below to learn more about how Visioneering Technologies’ revolutionary NaturalVue MF Multi Focal 1-day contact lens has been shown to address the progression of myopia in children.

Read More

Good Habits for healthy eyes – Visioneering Technologies’ seven tips for keeping your eyes healthy

Written by Dr Sally Dillehay, Chief Medical Officer, Visioneering Technologies (ASX:VTI) on 4/6/2018
1. Look for warning signs of changes in your vision If you start noticing significant changes in your vision or your children are experiencing eyesight difficulties, see your eye doctor immediately. Being proactive and seeking the opinion of an eye doctor could make all the difference in the lifespan of your eyes’ health.
Read More

Visioneering Technologies’ sets its sights on tackling the myopia epidemic

Written by Stephen Snowdy, PhD on 4/3/2018

By 2050 half of the world’s population will be myopic. In Australia and New Zealand alone, this number is expected to grow from four million in 2000 to a massive 22 million people by 2050. Clearly, myopia is a global epidemic.

Read More
  • All Announcements

VTI

/ Last updated

Open



Previous Close

High



Low

Volume



Turnover

52 week range

-

Market Cap


Company Announcements Date
Showing - of

  • Stock Chart

  • Key Documents

  • Governance Documents

  • Investor Contacts

Investor Enquiries

Media Relations

Computershare Registry